| | Principal Investigators
| Robert B. Innis, M.D., Ph.D. |
 |
|
Dr.
Innis received his B.S. degree from Yale University in
1974 and an M.D. from Johns Hopkins in 1978. He obtained
a Ph.D. Neuropharmacology from Johns Hopkins in 1981 under
the mentorship of Solomon Snyder. After completing a residency
in psychiatry at Yale University in 1984, he joined their
faculty in the Departments of Psychiatry and Pharmacology.
Dr. Innis left Yale in 2001 to become Chief of The
Molecular Imaging Branch, a new laboratory at NIMH
with an emphasis on brain imaging using PET (positron
emission tomography). |
| Research Interests |
Dr. Innis serves as Chief of the Molecular Imaging Branch (MIB), which employs several neuroimaging techniques to explore molecular and chemical mechanisms associated with neural function in health and disease. The primary methodologies used by this Branch are PET (positron emission tomography) and NMR (nuclear magnetic resonance). New PET radiotracers are synthesized for use as in vivo ligands to measure many different molecular targets, including membrane-bound receptors, proteins associated with intracellular signal transduction, and ones that reflect gene expression. Several NMR methods are also studied to measure molecular targets (magnetic resonance spectroscopy (MRS), local neuronal activity (functional MRI or fMRI), and structure of the brain (structural MRI).
This Branch has three sections and one unit: 1) Section on PET Radiopharmaceutical Sciences (Chief, Victor Pike, PhD), 2) Section on PET Neuroimaging Sciences (Chief, Robert Innis, MD, PhD), and 3) Section on Neuroimaging in Mood and Anxiety Disorders (Chief, Wayne Drevets, MD), and 4) Unit on Magnetic Resonance Spectroscopy (Chief, Jun Shen). Multimodal imaging studies are encouraged - e.g., combining MRS measurements of glutamate turnover with PET measurements dopaminergic neurotransmission.
Dr. Innis’s personal research interests are primarily connected to the first two sections. These Sections on Radiopharmaceuticals and Neuroimaging are focused PET, with a smaller effort in SPECT (single photon emission computed tomography). These sections have a strong methodological orientation, with state-of-the-art facilities to develop, evaluate, and then apply new radiotracers for in vivo imaging. New radiotracers are synthesized and then rigorously evaluated in animals (rodents and primates) to assess their utility to localize, quantify, and measure the functional status of their targets. Promising candidate radiotracers are extended to human subjects, first in healthy subjects and then in relevant patient populations.
See the following web site for the most up-to-date information on Dr. Innis’s laboratory, including recent findings, representative publications in pdf format, and current studies. http://intramural.nimh.nih.gov/mood/proginfo/mib/neuro.htm
|
| Representative Selected Recent Publications: |
- J.A. Rodriguez-Gomez, J.-Q. Lu, I. Velasco, S. Rivera, S.S. Zoghbi, J-S. Liow, J.L. Musachio, J. Shah, F.T. Chin, M.S. Crescenzo, H. Toyama, J. Seidel, M.V. Green, P.K. Thanos, M. Ichise, V.W. Pike, R.B. Innis and R.M. McKay.
Functional characterization of embryonic stem cell-derived dopamine neurons in a rodent model of Parkinson disease.
Stem Cells, 25: 918-928, 2007
- F. Yasuno, A.K. Brown, S.S. Zoghbi, J.H. Krushinski, E. Chernet, J. Tauscher, J. Schaus, L. Phebus, R.L. A.K. Chesterfield, C. Felder, Gladding, J. Hong, C. Halldin, V.W. Pike, and R.B. Innis.
The PET radioligand [11C]MePPEP binds reversibly and with high specific signal to cannabinoid CB1 receptors in nonhuman primate brain.
Neuropsychopharmacology. in press.
- Y.H. Ryu, J.-S. Liow, S.S. Zoghbi, M. Fujita, J. Collins, D. Tipre, J. Sangare, J. Hong, V.W. Pike, and R.B. Innis.
Disulfiram inhibits defluorination of [18F]FCWAY, reduces bone radioactivity, and enhances visualization of radioligand binding to 5-HT1A receptors in brain
J. Nucl. Med., 48: 1154 � 1161, 2007.
- M. Imaizumi, E. Briard, S.S. Zoghbi, J. Hong, J.L. Musachio, R. Gladding, V.W. Pike, R.B. Innis, and M. Fujita.
Kinetic evaluation in nonhuman primates of two new PET ligands for peripheral benzodiazepine receptors in brain.
Synapse. 61: 595-605, 2007.
- M. Fujita, M. Imaizumi, C. D'Sa, S.S. Zoghbi, M.S. Crescenzo, J. Hong, J.L. Musachio, A.D. Gee, J. Seidel, M.V. Green, V.W. Pike, R.S. Duman, and R.B. Innis.
In vivo and in vitro measurement of brain phosphodiesterase 4 in rats after antidepressant treatment Synapse, 61: 78-86, 2007.
- M. Imaizumi, H.-J. Kim, S.S. Zoghbi, E. Briard, J. Hong, J.L. Musachio, C. Ruetzler, D.-M. Chuang, V.W. Pike, R.B. Innis, and M. Fujita.
PET imaging with [11C]PBR28 can localize and quantify upregulated peripheral benzodiazepine receptors associated with cerebral ischemia in rat.
Neurosci. Lett. 411, 200-205, 2007.
|
|
|
|
|
